NYSE:ABBV 17 August 2025 - 12 February 2026

AbbVie stock (ABBV): FDA clears new Venclexta-Calquence CLL combo — what to watch Monday
····

AbbVie stock (ABBV): FDA clears new Venclexta-Calquence CLL combo — what to watch Monday

U.S. regulators approved a new first-line regimen for chronic lymphocytic leukemia combining AbbVie’s Venclexta and AstraZeneca’s Calquence, citing improved progression-free survival in the AMPLIFY study. AbbVie shares closed Friday up 0.21% at $224.81. Barclays initiated coverage with an overweight rating and a $275 price target. Investors await market reaction when trading resumes Monday.
February 22, 2026
AbbVie stock jumps as Botox Medicare lawsuit puts Washington back in focus
······

AbbVie stock jumps as Botox Medicare lawsuit puts Washington back in focus

AbbVie shares rose nearly 3% after the company sued U.S. health agencies to block Medicare price controls for Botox. The lawsuit argues Botox should be exempt from the Inflation Reduction Act’s negotiation program as a plasma-derived product. Investors are watching for early court developments and the Medicare timeline for 2028 prices. The case was assigned to U.S. District Judge Carl Nichols.
February 12, 2026
Senolytic Drugs
··········

The Secret “Zombie Cell” Killers: Niche Senolytic Drugs Fighting Aging’s Clock

A Mayo Clinic-led Phase 2 trial published July 2024 found dasatinib plus quercetin modestly increased wrist bone density in older women with high senescent-cell burden. Unity Biotechnology’s foselutoclax improved vision in diabetic macular edema patients after a single injection. About 20 senolytic clinical trials are underway worldwide, with Alzheimer’s disease results expected in 2025.
August 17, 2025